Chemotherapy-Induced Nausea and Vomiting

Lohr, Lisa

doi:10.1097/ppo.0b013e31816a0f07

Cited by 113 publications

(83 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chemotherapy-induced nausea and vomiting (CINV) is the most common side effect of cancer patients treated with highly emetogenic chemotherapy (1) and has a significant effect on the patients' daily functioning and well-being (2). Poor control of acute CINV, which occurs within 24 h after chemotherapy, may be used as a predictor of delayed CINV (3).…”

Section: Introductionmentioning

confidence: 99%

Association of ABCB1, 5-HT3B Receptor and CYP2D6 Genetic Polymorphisms with Ondansetron and Metoclopramide Antiemetic Response in Indonesian Cancer Patients Treated with Highly Emetogenic Chemotherapy

Perwitasari¹,

Wessels²,

Straaten³

et al. 2011

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Objective: Suboptimal treatment of chemotherapy-induced nausea and vomiting and unsatisfactory response to antiemetic drugs cause impairment of cancer patient's daily functioning. This study was aimed to investigate the association of selected germline polymorphisms with ondansetron and metoclopramide response in Indonesian cancer patients treated with highly emetogenic chemotherapy. Methods: We enrolled 202 chemotherapy naïve patients treated with cisplatin at a dosage of !50 mg/m 2 as monotherapy or as combined chemotherapy. Ondansetron 8 mg and dexamethasone 8 mg intravenously were the standard antiemetic therapy for prevention of acute chemotherapy-induced nausea and vomiting. Metoclopramide 10 mg orally, three times per day as fixed prescription, was given until 5 days after chemotherapy to prevent delayed chemotherapy-induced nausea and vomiting. Primary and secondary outcomes were the occurrence of chemotherapy-induced nausea and vomiting in the acute and delayed phase. The following single-nucleotide polymorphisms were determined in ABCB1: rs1045642, rs2032582 and rs1128503; in 5-HT3B-R: rs45460698, rs4938058 and rs7943062; and in CYP2D6: rs16947 (CYP2D6*2), rs3892097 (CYP2D6*4) and rs1065852 (CYP2D6*10) using Taqman assays. Results: During the acute phase, 21.8 and 30.2% patients experienced Grade 3 and 4 nausea and vomiting, respectively, whereas 38.6% patients experienced nausea and/or vomiting in the delayed phase. Carriers of the CTG haplotype of the ABCB1 gene experienced Grade 3 and 4 chemotherapy-induced nausea and vomiting more often than other haplotypes in the delayed phase (P , 0.05). No associations were found with the 5-HT3B receptor haplotypes and CYP2D6-predicted phenotypes. Conclusions: Our study shows that in Indonesian cancer patients treated with highly cytostatic emetogenic, carriership of the CTG haplotype of the ABCB1 gene is related to an increased risk of delayed chemotherapy-induced nausea and vomiting.

show abstract

Section: Introductionmentioning

confidence: 99%

Association of ABCB1, 5-HT3B Receptor and CYP2D6 Genetic Polymorphisms with Ondansetron and Metoclopramide Antiemetic Response in Indonesian Cancer Patients Treated with Highly Emetogenic Chemotherapy

Perwitasari¹,

Wessels²,

Straaten³

et al. 2011

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Conversely, patients with a history of high alcohol consumption have lower risk of CINV. 3,4 A study of breast cancer patients has recently become available, and analysis in those receiving cyclophosphamide with doxorubicin or epirubicin combination chemotherapy confirmed that younger age (,55 years), no or low alcohol intake (0-4 drinks per week) and a history of pregnancyrelated morning sickness are risk factors for CINV. 5 These findings were supported by another study based on other cancer patients who received cisplatin-based chemotherapy, 6 in which female gender was also identified as a risk factor.…”

Section: Patient-related Factorsmentioning

confidence: 99%

Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients

Chan¹,

Park²

2011

BCTT

View full text Add to dashboard Cite

Chemotherapy-induced nausea and vomiting (CINV) continues to be one of the most distressing side effects of chemotherapy in breast cancer patients, which can result in poor compliance to therapy that may, in turn, affect overall survival. The extent of CINV is dependent on the emetogenic potential of the individual cytotoxic agents or regimens employed as well as certain patient factors. Advances in our understanding in the pathophysiology of CINV and the identification of risk factors have enabled the utilization of appropriate antiemetic regimens to improve the control of CINV. Most of the chemotherapy regimens used in this patient population are considered to be moderately emetogenic; 60%-90% of chemotherapeutic regimens used in breast cancer patients cause nausea and vomiting, amongst which regimens doxorubicin-cyclophosphamide (AC) combination is commonly regarded as of relatively higher emetogenicity. Currently, corticosteroids, 5-hydroxytryptamine 3 (5-HT3) receptor antagonists, and neurokinin 1 (NK-1) receptor antagonists are the three classes of antiemetic agents with the highest therapeutic index, which have been supported by data from large-scale randomized clinical trials. Treatment guidelines enable physicians to integrate the latest research data into their clinical practices. This review focuses on the three classes of antiemetic therapy options for CINV in breast cancer patients, as well as their safety and tolerability profiles. Recommendations from major guidelines/consensus including from the Multinational Association for Supportive Care in Cancer/European Society of Medical Oncology (MASCC/ESMO), the American Society of Clinical Oncology (ASCO), and the US National Comprehensive Cancer Network (NCCN), are also discussed. With the correct use of antiemetic regimens, chemotherapy-induced vomiting could be prevented in the majority of patients. However, chemotherapy-induced nausea remains an important symptom and a challenge for physicians to manage.

show abstract

“…[3] Other side effects are alopecia, weakness, loss of weight, fever, peripheral neuropathy and other gastrointestinal side effects like Diarrhea, Loss of appetite, Anorexia, Vomiting, Constipation, Stomatitis, Burning sensation. [4,5] Expenses and associated side effects of anticancer drugs have provoked the research for drugs with minimum side effects and low in cost. [6] Plants have been used as an age old remedy for treatment of cancer.…”

Section: World Journal Of Pharmacy and Pharmaceutical Sciencesmentioning

confidence: 99%